The Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis Trial: Reanalysis Using the FDA "On Label" Criteria.

Adnan I QureshiMuhammad F IshfaqVamshi K S BalasettiIryna LobanovaGuven UzunFarhan SiddiqCamilo R Gomez

Published in: Journal of neuroimaging : official journal of the American Society of Neuroimaging (2020)

The new FDA "on label" criteria may identify a small group of people, who may benefit from intracranial stent placement due to higher risk of primary endpoint in those treated with best medical treatment.

Keyphrases

healthcare
optic nerve
study protocol
phase iii
randomized controlled trial
phase ii
antiplatelet therapy
combination therapy
coronary artery disease
open label
newly diagnosed
acute coronary syndrome
atrial fibrillation